Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Genmab
(OTCPK:GNMSF)
Intraday
$274.35
4.48
[1.66%]
Get Report
Watch
Perks
Buy
Compare Brokers
$274.35
4.48
[1.66%]
At close: Apr 26
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Genmab Stock (OTC:GNMSF)
Genmab Stock (OTC: GNMSF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, August 06, 2020
GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
Shivdeep Dhaliwal
-
Aug 6, 2020, 3:59AM
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
-
Mar 24, 2020, 11:35AM
Tuesday, August 13, 2019
Stocks That Hit 52-Week Highs Of Tuesday
Lisa Levin
-
Aug 13, 2019, 10:28AM
Monday, August 12, 2019
Stocks That Hit 52-Week Highs Of Monday
Lisa Levin
-
Aug 12, 2019, 10:31AM
Sunday, October 25, 2015
Genmab Announces $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga
-
Oct 25, 2015, 5:52PM
Monday, October 05, 2015
Genmab Reaches $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga
-
Oct 5, 2015, 9:53AM
Friday, September 25, 2015
US Stock Futures Jump Ahead Of GDP Report
Benzinga
-
Sep 25, 2015, 7:30AM
Genmab Announces CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma
Benzinga
-
Sep 25, 2015, 5:25AM
Saturday, September 19, 2015
Genmab Announces FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL
Benzinga
-
Sep 19, 2015, 10:03AM
Friday, September 04, 2015
Genmab Announces FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
Benzinga
-
Sep 4, 2015, 2:28PM
Friday, August 14, 2015
US Stock Futures Slip Ahead Of Economic Data
Benzinga
-
Aug 14, 2015, 7:11AM
Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
Benzinga
-
Aug 14, 2015, 6:39AM
Monday, April 27, 2015
Genmab Announces Phase III Study of Arzerra Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
Benzinga
-
Apr 27, 2015, 10:27AM
Monday, March 16, 2015
Genmab Retains Partial Rights for HuMax-TAC-ADC; Won't Exercise Co-development Right
Benzinga
-
Mar 16, 2015, 6:44AM
Monday, August 11, 2014
Genmab Announces Jannsen to Start New Phase III Study of Daratumumab in Front Line Multiple Myeloma
Benzinga
-
Aug 11, 2014, 9:26AM
